Axa
IMVT icon

Axa’s Immunovant IMVT Stock Holding History

Axa’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-98,683
Closed -$2.44M – 1092
2024
Q4 		$2.44M Sell
98,683
-155
-0.2% -$4.4K 0.01% 715
2024
Q3 		$2.82M Buy
98,838
+28
+0% +$826 0.01% 681
2024
Q2 		$2.61M Buy
98,810
+56
+0.1% +$1.59K 0.01% 694
2024
Q1 		$3.19M Buy
98,754
+28
+0% +$1.02K 0.01% 668
2023
Q4 		$4.16M Sell
98,726
-2,388
-2% -$87.9K 0.01% 591
2023
Q3 		$3.88M Buy
+101,114
New +$2.29M 0.01% 581

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Axa's IMVT Position: Q1 2025 in Review

Axa sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 98,683 shares — an estimated $2.44M sold.

Axa first reported a position in IMVT in Q3 2023 and held it in 6 quarters. The position peaked at $4.16M in Q4 2023. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

  • Axa reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
  • Axa sold 98,683 Immunovant shares in Q1 2025, an estimated $2.44M.
  • Axa first reported a position in Immunovant in Q3 2023 and held it in 6 quarters.
  • Axa's Immunovant position peaked at $4.16M in Q4 2023.
  • 193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on Axa's 13F filing for Q1 2025, filed 15 May 2025.